SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Dario Pitocco; Linda Tartaglione; Luca Viti; Mauro Di Leo; Alfredo Pontecorvi; Salvatore Caputo

doi:10.1016/j.diabres.2020.108162

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Dario Pitocco, Linda Tartaglione, Luca Viti, Mauro Di Leo, Alfredo Pontecorvi, Salvatore Caputo

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.

Lingua originale	English
pagine (da-a)	1-3
Numero di pagine	3
Rivista	Diabetes Research and Clinical Practice
Volume	163
DOI	https://doi.org/10.1016/j.diabres.2020.108162
Stato di pubblicazione	Pubblicato - 2020

Keywords

ACE 2
COVID 19
DIABETES
DPP4

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.diabres.2020.108162

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{92bc024f83df4c03b2401fcee0474d3b,

title = "SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?",

abstract = "Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn't represent a plausible approach to mitigate COVID-19.",

keywords = "ACE 2, COVID 19, DIABETES, DPP4, ACE 2, COVID 19, DIABETES, DPP4",

author = "Dario Pitocco and Linda Tartaglione and Luca Viti and {Di Leo}, Mauro and Alfredo Pontecorvi and Salvatore Caputo",

year = "2020",

doi = "10.1016/j.diabres.2020.108162",

language = "English",

volume = "163",

pages = "1--3",

journal = "Diabetes Research and Clinical Practice",